Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.
| Revenue (Most Recent Fiscal Year) | $2.50B |
| Net Income (Most Recent Fiscal Year) | $-204.15M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.91 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.28 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3342.49 |
| Pre-Tax Margin (Trailing 12 Months) | -7.82% |
| Net Margin (Trailing 12 Months) | -7.95% |
| Return on Equity (Trailing 12 Months) | -6.17% |
| Return on Assets (Trailing 12 Months) | -2.98% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.93 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.72 |
| Inventory Turnover (Trailing 12 Months) | 5.60 |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.39 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.21 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.13 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.17 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 185.08M |
| Free Float | 182.56M |
| Market Capitalization | $10.54B |
| Average Volume (Last 20 Days) | 1.44M |
| Beta (Past 60 Months) | 1.24 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.36% |
| Percentage Held By Institutions (Latest 13F Reports) | 88.82% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |